低级别胶质瘤患者的心理肿瘤学痛苦:单中心研究
HADS筛查显示20.8%患者痛苦水平升高,相关因素包括既存精神疾病和服用精神药物;无组织病理诊断者HRQoL和未来不确定性评分更高。结论建议频繁筛查痛苦,必要时可用HRQoL问卷替代。
要点
- LGG患者中约20.8%存在心理痛苦升高,应常规筛查。
- 既存精神疾病和服用精神药物是痛苦升高的显著相关因素。
- 无组织病理诊断者未来不确定性及HRQoL评分更高,需关注。
核心结论
- LGG患者心理痛苦常见,需频繁筛查,既存心理压力者应提供心理肿瘤学支持。
主要发现
- HADS筛查显示20.8%患者痛苦水平升高(平均评分1.21,95%CI 1.15-1.28)。
- 痛苦升高与既存精神疾病(p=0.003)和服用精神药物(p=0.029)显著相关。
- 无组织病理诊断者HRQoL(p=0.022)、整体健康条目(p=0.015)和未来不确定性(p=0.047)评分显著更高。
- 痛苦升高与HRQoL问卷部分子项显著相关(p<0.001)。
临床怎么用
- 对LGG患者应频繁进行心理痛苦筛查,无专用工具时可用HRQoL问卷替代。
- 对既存心理压力者应提供额外心理肿瘤学支持,不受筛查时间或肿瘤诊断状态影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients diagnosed with low-grade glioma (LGG) must live with constant knowledge of an upcoming malignant tumor transformation which may lead to increased anxiety and reduced quality of life. Here, we (1) analyzed the prevalence and risk factors for distress in LGG patients using (2) different screening tools to subsequently (3) evaluate their need for psychological support. METHOD: Patients with LGG-suspicious findings in MRI studies as well as patients with histopathological confirmed LGG were screened using three established self-assessment instruments (Hospital Anxiety and Depression Scale, Distress Thermometer, EORTC-QLQ-C30-BN20). Screening results were correlated with sociodemographic factors. RESULTS: One hundred forty-nine patients (74 men and 75 women) were prospectively included. Patients were further divided into different subgroups regarding the time of screening and diagnosis. An increased level of distress was observed in 20.8% (mean score 1.21, 95% CI 1.15-1.28) of all patients screened by HADS. Significant associated factors were pre-existing psychiatric disorders (p = 0.003) and psychotropic medication (p = 0.029). HRQoL (p = 0.022) and global health item (p = 0.015), as well as future uncertainty (p = 0.047), assessed by the EORTC-QLQ-C30-BN20 were significantly higher in those patients without histopathological diagnosis. Increased distress was significantly correlated with results in chosen sub-items of the HRQoL questionnaire (p < 0.001). CONCLUSIONS: Our results demonstrate the need for frequent distress screening. If specific tools are not available, HRQoL questionnaires can also be used. Patients with pre-existing psychological stress should be offered additional psychooncological support, irrespectively of the time of screening or tumor diagnosis. CLINICAL TRIAL REGISTRATION NUMBER: 4087.
引用
- Ley A, Kamp M, von Sass C, et al. Psychooncological distress in low-grade glioma patients-a monocentric study. Acta Neurochir (Wien). 2021. PMID: 34159449. doi:10.1007/s00701-021-04863-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。